Filippo Confalonieri, Antonio La Rosa, Giovanni Ottonelli, Gianmaria Barone, Vanessa Ferraro, A. Di Maria, Mary Romano, A. Randazzo, J. Vallejo-Garcia, Paolo Vinciguerra, G. Petrovski
{"title":"Retinitis Pigmentosa and Therapeutic Approaches: A Systematic Review","authors":"Filippo Confalonieri, Antonio La Rosa, Giovanni Ottonelli, Gianmaria Barone, Vanessa Ferraro, A. Di Maria, Mary Romano, A. Randazzo, J. Vallejo-Garcia, Paolo Vinciguerra, G. Petrovski","doi":"10.3390/jcm13164680","DOIUrl":null,"url":null,"abstract":"Background: Retinitis pigmentosa (RP) is a group of hereditary retinal dystrophies characterized by progressive degeneration of photoreceptor cells, which results in debilitating visual impairment. This systematic review aims to evaluate the efficacy and safety of emerging treatment modalities for RP, including gene therapy, mesenchymal-cell-based approaches, and supplementary interventions. Methods: A comprehensive search of electronic databases was conducted to identify relevant studies published up to February 2024. Studies reporting outcomes of treatment interventions for RP, including randomized controlled trials, non-randomized studies, and case series, were included. Data extraction and synthesis were performed according to predefined criteria, focusing on assessing the quality of evidence and summarizing key findings. Results: The search yielded 13 studies meeting inclusion criteria, encompassing diverse treatment modalities and study designs. Gene therapy emerged as a promising therapeutic approach, with several studies reporting favorable outcomes regarding visual function preservation and disease stabilization. Mesenchymal-cell-based therapies also demonstrated potential benefits, although evidence remains limited and heterogeneous. Supplementary interventions, including nutritional supplements and neuroprotective agents, exhibited variable efficacy, with conflicting findings across studies. Conclusions: Despite the lack of definitive curative treatments, emerging therapeutic modalities promise to slow disease progression and preserve visual function in individuals with RP. However, substantial gaps in evidence and heterogeneity in study methodologies underscore the need for further research to elucidate optimal treatment strategies, refine patient selection criteria, and enhance long-term outcomes. This systematic review provides a comprehensive synthesis of current evidence and highlights directions for future research to advance the care and management of individuals with RP.","PeriodicalId":510228,"journal":{"name":"Journal of Clinical Medicine","volume":"45 21","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/jcm13164680","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Retinitis pigmentosa (RP) is a group of hereditary retinal dystrophies characterized by progressive degeneration of photoreceptor cells, which results in debilitating visual impairment. This systematic review aims to evaluate the efficacy and safety of emerging treatment modalities for RP, including gene therapy, mesenchymal-cell-based approaches, and supplementary interventions. Methods: A comprehensive search of electronic databases was conducted to identify relevant studies published up to February 2024. Studies reporting outcomes of treatment interventions for RP, including randomized controlled trials, non-randomized studies, and case series, were included. Data extraction and synthesis were performed according to predefined criteria, focusing on assessing the quality of evidence and summarizing key findings. Results: The search yielded 13 studies meeting inclusion criteria, encompassing diverse treatment modalities and study designs. Gene therapy emerged as a promising therapeutic approach, with several studies reporting favorable outcomes regarding visual function preservation and disease stabilization. Mesenchymal-cell-based therapies also demonstrated potential benefits, although evidence remains limited and heterogeneous. Supplementary interventions, including nutritional supplements and neuroprotective agents, exhibited variable efficacy, with conflicting findings across studies. Conclusions: Despite the lack of definitive curative treatments, emerging therapeutic modalities promise to slow disease progression and preserve visual function in individuals with RP. However, substantial gaps in evidence and heterogeneity in study methodologies underscore the need for further research to elucidate optimal treatment strategies, refine patient selection criteria, and enhance long-term outcomes. This systematic review provides a comprehensive synthesis of current evidence and highlights directions for future research to advance the care and management of individuals with RP.
背景:视网膜色素变性(RP)是一组遗传性视网膜营养不良症,其特点是感光细胞进行性变性,从而导致衰弱性视力损伤。本系统综述旨在评估新出现的 RP 治疗方法的有效性和安全性,包括基因疗法、基于间充质细胞的方法和辅助干预措施。方法:对电子数据库进行全面检索,以确定截至 2024 年 2 月发表的相关研究。纳入了报告 RP 治疗干预结果的研究,包括随机对照试验、非随机研究和病例系列。根据预先确定的标准进行数据提取和综合,重点评估证据的质量并总结主要发现。结果:搜索结果有 13 项研究符合纳入标准,包括不同的治疗方式和研究设计。基因疗法是一种很有前景的治疗方法,有几项研究报告了在视觉功能保护和疾病稳定方面的良好结果。基于间充质细胞的疗法也显示出了潜在的益处,尽管证据仍然有限且不尽相同。补充性干预措施,包括营养补充剂和神经保护剂,显示出不同的疗效,不同研究的结果相互矛盾。结论:尽管缺乏确切的治疗方法,但新出现的治疗模式有望延缓 RP 患者的疾病进展并保护其视觉功能。然而,证据上的巨大差距和研究方法上的异质性凸显了进一步研究的必要性,以阐明最佳治疗策略、完善患者选择标准并提高长期疗效。本系统性综述对目前的证据进行了全面综合,并强调了未来研究的方向,以促进对 RP 患者的护理和管理。